ClinicalTrials.gg
RecruitingNCT06438146LIROHUpdated May 31, 2024

LIROH - Liraglutide for Obesity in HIV

A Phase 4 interventional study of Liraglutide in Obesity and HIV Infections, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in South Africa. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.

Sponsored by Brigham and Women's Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Planned enrollment
52nd of 79
40 · median 70
Started
2024
with 1 other
Phase 4
37 of 79
4 open now
Registered
75th of 79
by date

Among the 79 studies testing liraglutide in Obesity, this one is the 52nd largest by planned enrollment, is one of 2 that started in 2024, is one of 37 in phase 4, and was the 75th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined by a BMI ≥30 kg/m2 who are on dolutegravir-based ART.

Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0 mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.

Read the detailed description

South Africa has the largest population of PLWH globally, with a prevalence of 17% in adults or 7.2 million PLWH. The rapid scale-up of ART programs has resulted in >6 million PLWH on treatment, significant gains in life expectancy, and a large population of aging PLWH. With increasing life expectancy, obesity and type 2 diabetes have become growing threats for PLWH in South Africa and globally. One recent study found that 63% of PLWH are overweight or obese, and 6% have diabetes in this setting.

This elevated risk of obesity in PLWH in South Africa is likely due to a confluence of both general considerations and HIV-specific factors. First, South Africa has experienced an accelerated background epidemic of metabolic disease in the general population with a prevalence of overweight and obesity that is nearly equal to that of high-income countries. Additionally, the International Diabetes Federation estimates that approximately 15.5 million adults are living with diabetes in the African Region, and projects it to grow to 41 million by 2045. As part of this background epidemic of metabolic disease, South Africa is also experiencing a nutrition transition, with widespread availability of processed and refined foods as well as sugar-sweetened beverages.

Regarding HIV-specific issues, in 2019 the first-line ART regimen for the South African national HIV treatment program transitioned to TLD. TLD is generally very safe and well-tolerated and has a high barrier to HIV resistance but this transition to this regimen has been associated with risk of excess weight gain at the population level. Both clinical trials and observational studies conducted in South Africa have shown substantial increases in body weight in those who are initiating this ART regimen newly and among those who are suppressed and switched, especially women. Given this, there is a growing risk of obesity in PLWH in this context and a need for management strategies to address this increasingly prevalent comorbidity.

Preventing the metabolic complications of HIV in South Africa and worldwide requires urgent solutions. To date, obesity management and diabetes prevention have largely consisted of behavioural interventions such as the Diabetes Prevention Program and related lifestyle modification efforts, focused on improving diet and increasing physical activity. However, in the past several years, novel anti-obesity pharmacologic agents such as the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown enormous promise for obesity management and diabetes prevention in people who are HIV-negative (8-10). However, this drug class has a very limited evidence base in PLWH and relatively scant data from sub-Saharan African populations.

Currently, liraglutide is the only GLP-1 RA approved for obesity management in South Africa and this protocol proposes to use the drug for its labelled indication of "weight loss in addition to diet and exercise in adults aged 18 and above who have: (1) a BMI of 30 or greater (obese) or (2) a BMI of greater than 27 and less than 30 (overweight) and weight related health problems (such as diabetes, high blood pressure, hypercholesterolemia, or obstructive sleep apnoea).

This evidence gap motivates further inquiry into GLP-1 RAs such as liraglutide as one potential approach to obesity management and prevention of diabetes in PLWH who have comorbid obesity in South Africa, with implications for PLWH in other contexts. In this proposal, the investigators seek to further this important area of inquiry by evaluating the acceptability of liraglutide along with lifestyle counselling in PLWH who have obesity and are stable on dolutegravir-based ART in South Africa.

03

Conditions studied

  • Obesity
  • HIV Infections

Keywords

  • HIV
  • Obesity
  • Liraglutide
  • Behavior
  • Exercise
  • Lifestyle counseling
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to give written to participate in the study
  2. Able to comply with all study procedures, including daily subcutaneous injections
  3. Adults ≥18 years old
  4. PLWH on dolutegravir-based ART for ≥6 months
  5. Documented -1 viral load in the past 6 months confirming the participant is virologically suppressed
  6. ≥30 kg/m2
  7. Desiring weight loss
  8. Willing to undertake lifestyle change
  9. Not on any weight loss agent for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Self-reported history of diabetes
  2. Current use of medications for diabetes
  3. Known to liraglutide, such as to a component of the drug
  4. Current pregnancy or desire to become pregnant
  5. History of pancreatitis
  6. History of thyroid disease
  7. History of harmful use of alcohol
  8. Clinically unstable in the opinion of the investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Lirgalutide

    Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.

    Drug: Liraglutide

Interventions

  • Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks. This corresponds to the following dosing schedule: Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration

    Also known as: Saxenda

06

What researchers measure

Primary outcomes

  1. Proportion of participants who screen and enroll among those approached

    This will be expressed in terms of the proportion of participants who attend screening and enrolment visits among the total number who are approached regarding interest in study participation.

    Time frame: Measured at screening

  2. Time to reach study enrollment target

    Time frame: Measured at enrollment

  3. Study retention rate at 12 weeks

    This will be expressed as a proportion of participants who remain in the study after the 12 week "on treatment" period among those enrolled.

    Time frame: Measured at Visit 4 at 12 weeks

  4. Study retention rate at 24 weeks

    This will be expressed as a proportion of participants who remain in the study after the full 24 weeks of study procedures are completed among those enrolled.

    Time frame: Measured at End of Study at 24 weeks

  5. Rate of adherence to treatment over 12 weeks

    The investigators will assess volume remaining in the injector pens and provide a percentage of doses per participant that remained unused at the end of the 12-week period on treatment.

    Time frame: Measured at Visit 4 at 12 weeks

  6. Embedded qualitative interviews regarding the acceptability of liraglutide for obesity management

    This will be open-ended responses to a brief exit interview about acceptability and feasibility.

    Time frame: Measured at End of Study at 24 weeks

Secondary outcomes

  1. Incidence of treatment-emergent adverse events as defined in this protocol

    The investigators will report incidence of TEAEs up to 24 weeks (12 weeks on + 12 weeks off treatment)

    Time frame: From the initiation of treatment until the date of a treatment-emergent adverse event, assessed up to 24 weeks.

  2. Incidence of serious adverse events (SAEs), as defined in this protocol

    The investigators will report incidence of SAEs up to 24 weeks (12 weeks on + 12 weeks off treatment)

    Time frame: From the initiation of treatment until the date of a serious adverse event, assessed up to 24 weeks.

  3. Change in body weight following 12 weeks on treatment

    Body weight will be measured in the study at both enrolment and after 12 weeks on treatment (Visit 4); these will be used to calculate a continuous change in kg.

    Time frame: Measured at Visit 4 at 12 weeks

  4. Change in body weight over 24 weeks (12 weeks on + 12 weeks off treatment)

    Body weight will be measured in the study at both enrolment and after 24 weeks on treatment (EOS); these will be used to calculate a continuous change in kg.

    Time frame: Measured at End of Study at 24 weeks

  5. Change in HbA1c following 12 weeks on treatment

    HbA1c will be measured at enrolment and at Visit 4; here investigators will calculate the difference between these measures (in %).

    Time frame: Measured at Visit 4 at 12 weeks

  6. Change in HbA1c over 24 weeks (12 weeks on + 12 weeks off treatment)

    HbA1c will be measured at enrolment and at EOS; here investigators will calculate the difference between these measures (in %).

    Time frame: Measured at End of Study at 24 weeks

  7. Change in fasting plasma glucose following 12 weeks on treatment

    Fasting glucose will be measured at enrolment and at Visit 4; investigators will calculate the difference between these measures (in mmol/L).

    Time frame: Measured at Visit 4 at 12 weeks

  8. Change in fasting plasma glucose over 24 weeks (12 weeks on + 12 weeks off treatment)

    Fasting glucose will be measured at enrolment and at EOS; investigators will calculate the difference between these measures (in mmol/L).

    Time frame: Measured at End of Study at 24 weeks

  9. Change in depressive symptoms following 12 weeks on treatment

    This will be defined as the difference in depression score per the Patient Health Questionnaire (PHQ-9) at enrolment and Visit 4. The minimum value is 1 and the maximum is 27, where the greater the total score, the greater severity of depression.

    Time frame: Measured at Visit 4 at 12 weeks

  10. Change in depressive symptoms over 24 weeks (12 weeks on + 12 weeks off treatment)

    This will be defined as the difference in depression score per the Patient Health Questionnaire (PHQ-9) at enrolment and EOS. The minimum value is 1 and the maximum is 27, where the greater the total score, the greater severity of depression.

    Time frame: Measured at End of Study at 24 weeks

  11. Change in physical activity level following 12 weeks on treatment

    This will be defined as the difference in physical activity expressed in MET-minutes per week, where MET minutes represent the amount of energy expended carrying out physical activity, per the International Physical Activity Questionnaire (IPAQ) at enrolment and Visit 4.

    Time frame: Measured at Visit 4 at 12 weeks

  12. Change in physical activity level over 24 weeks (12 weeks on + 12 weeks off treatment)

    This will be defined as the difference in physical activity expressed in MET-minutes, where MET minutes represent the amount of energy expended carrying out physical activity, per week per the International Physical Activity Questionnaire (IPAQ) at enrolment and EOS.

    Time frame: Measured at End of Study at 24 weeks

  13. Change in dietary habits following 12 weeks on treatment

    This will be defined as the difference in total servings of fruits and vegetables, change in frequency of sugar-sweetened beverage intake, and change frequency of fast food intake from enrolment to Visit 4.

    Time frame: Measured at Visit 4 at 12 weeks

  14. Change in dietary habits over 24 weeks (12 weeks on + 12 weeks off treatment)

    This will be defined as the difference in total servings of fruits and vegetables, change in frequency of sugar-sweetened beverage intake, and change frequency of fast food intake from enrolment to EOS.

    Time frame: Measured at End of Study at 24 weeks

Other outcomes

  1. Change in blood pressure following 12 weeks on treatment

    Systolic blood pressure change in mm Hg

    Time frame: Measured at Visit 4 at 12 weeks

  2. Change in blood pressure over 24 weeks (12 weeks on + 12 weeks off treatment)

    Blood pressure change in mm Hg

    Time frame: Measured at End of Study at 24 weeks

  3. Change in lipids following 12 weeks on treatment

    Change in total cholesterol

    Time frame: Measured at Visit 4 at 12 weeks

  4. Change in lipids over 24 weeks (12 weeks on + 12 weeks off treatment)

    Change in total cholesterol

    Time frame: Measured at End of Study at 24 weeks

  5. Change in waist circumference following 12 weeks on treatment

    Change in waist circumference in cm

    Time frame: Measured at Visit 4 at 12 weeks

  6. Change in waist circumference over 24 weeks (12 weeks on + 12 weeks off treatment)

    Change in waist circumference in cm

    Time frame: Measured at End of Study at 24 weeks

  7. Change in quality of life following 12 weeks on treatment per the World Health Organization's Quality of Life Instrument in HIV Infection

    Change in quality of life scale score (scale of 0 - 100)

    Time frame: Measured at Visit 4 at 12 weeks

  8. Change in quality of life over 24 weeks (12 weeks on + 12 weeks off treatment) per the World Health Organization's Quality of Life Instrument in HIV Infection

    Change in quality of life scale score (scale of 0 - 100)

    Time frame: Measured at End of Study at 24 weeks

  9. Change in sleep quality following 12 weeks on treatment per the Pittsburgh Sleep Quality Index

    Change in sleep quality scale score (global score range of 0 to 21 where score of 5 or greater indicates poor sleep)

    Time frame: Measured at Visit 4 at 12 weeks

  10. Change in sleep quality over 24 weeks (12 weeks on + 12 weeks off treatment) per the Pittsburgh Sleep Quality Index

    Change in sleep quality scale score (global score range of 0 to 21 where score of 5 or greater indicates poor sleep)

    Time frame: Measured at End of Study at 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Africa Health Research Institute Clinical Trials Unit
    Mtubatuba, 3935, South Africa
    Recruiting
    • Ngundu Behuhuma, MBChB · Contactngundu.behuhuma@ahri.org · 082 964 0652
    • Ngundu Behuhuma, MBChB · Principal investigator
    • Mark Siedner, MD, MPH · Principal investigator
    • Limakatso Lebina, MBChB · Principal investigator
    • Jennifer Manne-Goehler, MD, ScD · Principal investigator
08

References and documents

Publications

  • Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, Serenata C, Akpomiemie G, Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P, Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill A. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24. PubMed 31339677 ↗
  • Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 Oct;7(10):e666-e676. doi: 10.1016/S2352-3018(20)30241-1. PubMed 33010240 ↗
  • Manne-Goehler J, Rahim N, van Empel E, de Vlieg R, Chamberlin G, Ihama A, Castle A, Mabweazara S, Venter WDF, Chandiwana N, Levitt NS, Siedner M. Perceptions of Health, Body Size, and Nutritional Risk Factors for Obesity in People with HIV in South Africa. AIDS Behav. 2024 Jan;28(1):367-375. doi: 10.1007/s10461-023-04152-7. Epub 2023 Aug 26. PubMed 37632604 ↗
  • Chandiwana NC, Siedner MJ, Marconi VC, Hill A, Ali MK, Batterham RL, Venter WDF. Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications. J Clin Endocrinol Metab. 2024 Jan 18;109(2):e478-e487. doi: 10.1210/clinem/dgad411. PubMed 37437159 ↗
  • Magodoro IM, Olivier S, Gareta D, Koole O, Modise TH, Gunda R, Herbst K, Pillay D, Wong EB, Siedner MJ. Linkage to HIV care and hypertension and diabetes control in rural South Africa: Results from the population-based Vukuzazi Study. PLOS Glob Public Health. 2022 Nov 2;2(11):e0001221. doi: 10.1371/journal.pgph.0001221. eCollection 2022. PubMed 36962629 ↗
  • Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sorrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619. PubMed 35015037 ↗
  • Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. PubMed 33625476 ↗
  • Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PubMed 33567185 ↗
  • Hyle EP, Bekker LG, Martey EB, Huang M, Xu A, Parker RA, Walensky RP, Middelkoop K. Cardiovascular risk factors among ART-experienced people with HIV in South Africa. J Int AIDS Soc. 2019 Apr;22(4):e25274. doi: 10.1002/jia2.25274. PubMed 30990252 ↗
  • Bailin SS, Gabriel CL, Wanjalla CN, Koethe JR. Obesity and Weight Gain in Persons with HIV. Curr HIV/AIDS Rep. 2020 Apr;17(2):138-150. doi: 10.1007/s11904-020-00483-5. PubMed 32072466 ↗

Individual participant data

Plan to share: Yes — Anonymized data as allowable

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The IPD data will be shared in accordance with AHRI Data Access Policy and Data Management Plan within two years of completion.

Access criteria: Access to the IPD and the associated documents will require completion of the online data access application form accessible on the AHRI Data repository. AHRI bona fide data users are required to abide by the data use conditions stipulated on the application for access to the data.

Data sharing details ↗ · data.ahri.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2025, 12 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 12 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 31, 2024
StartActual
May 2, 2024
Primary completionEst.
May 2025
CompletionEst.
May 2025
Last update
May 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06438146
Responsible party
Jennifer M. Manne-Goehler, MD, SCD (Assistant Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
May 31, 2024
Start date
May 2, 2024
Primary completion
May 2025 (estimated)
Completion
May 2025 (estimated)
Last update
May 31, 2024

Study contacts

Jennifer Manne-Goehler, MD, ScD
Contact
jmanne@bwh.harvard.edu
7542246060
Jennifer Manne-Goehler, MD, ScD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion